Infectious disease
According to a Wall Street Journal report, Takeda has assigned about 40 staffers to work on the project, which was only conceptual a few weeks ago until they triggered the program.
Scangos, who currently helms Vir Biotechnology, is expected to coordinate the industry’s response to the increasing coronavirus threat.
The novel coronavirus that causes the disease COVID-19 continues to spread and has now been diagnosed in more than 50 countries.
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns.
PRESS RELEASES